eXoZymes
Develops AI-assisted enzymes for making small molecules in cell-free bioreactors.
Something off on this page? Send us feedback.
Profile
Develops AI-assisted enzymes that operate outside living cells to turn feedstocks into small molecules. Its development-stage biosolutions target potential pharmaceutical ingredients, nutraceuticals, and fuels.
Engineers AI-assisted enzymes for cell-free bioreactors that convert feedstocks into small molecules. The company describes these systems as biosolutions. The resulting biosolutions target potential pharmaceutical ingredients, nutraceuticals, and fuels rather than a mature product catalog. The platform is rooted in enzyme systems designed to operate outside living cells.
Based in Monrovia, California, the small, R&D-heavy company combines founder scientific leadership with a CEO installed shortly before its IPO. Commercial progress depends on scaling the technology and executing with partners. Its public materials frame current work around NCT and biomanufacturing applications.
Company facts
Key statistics
Year to date −33.2% · Average volume (30d) 6.3K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | — | −$0.33 | — | — | — | — | −3.00% |
| May 14, 2026Q1 FY26 | — | −$0.28 | — | — | — | — | −2.59% |
| Mar 30, 2026Q4 FY25 | — | −$0.32 | — | — | — | — | +2.88% |
| Nov 13, 2025Q3 FY25 | — | −$0.27 | — | — | — | — | −6.95% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | −$70.5K | −$72.3K | −$71.6K | $214.4K | −$74.1K | $0 | |
| Operating income | −$2.0M | −$2.5M | −$2.5M | −$2.7M | −$2.4M | −$3.0M | |
| Net income | −$1.9M | −$2.4M | −$2.3M | −$2.7M | −$2.4M | −$2.9M | |
| Diluted EPS | −$0.22 | −$0.28 | −$0.27 | −$0.32 | −$0.28 | −$0.33 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $5.7M · Total debt $1.1M · Total assets $8.0M · Shareholders' equity $3.7M
Dividends
No dividends on record.
Ownership
Shares outstanding 9.28M · Float 2.48M · 26.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Christopher A. Marlett | 4.16M | 43.61% | 13D | Nov 18, 2024 |
| Tyler Paz Korman · officer: Chief Scientific Officer | 762.8K | 8.22% | Form 4 | Aug 25, 2026 |
| Paul Hideo Opgenorth · officer: Vice President, Development | 645.1K | 6.95% | Form 4 | Apr 8, 2026 |
| James U Bowie | 597.4K | 6.27% | 13D | Nov 18, 2024 |
| Edgardo Javier Rayo · director | 77.9K | 0.84% | Form 4 | Mar 25, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 9, 2026 | Tyler Paz Korman | officer: Chief Scientific Officer | −750 | $10.53 |
| Apr 8, 2026 | Tyler Paz Korman | officer: Chief Scientific Officer | −750 | $10.04 |
Peers
- Codexis
Directed-enzyme engineering for scalable therapeutic manufacturing
- LanzaTech Global
Carbon-to-chemicals and fuel production through gas fermentation
- Ginkgo Bioworks
Cell-programming platform for industrial and biopharma applications
- Twist Bioscience
Synthetic-biology platform spanning DNA, RNA, proteins, and discovery
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| eXoZymes | $7.25 | −1.23% | $66.5M | — | — | — | — |
| Codexis | $1.61 | +1.90% | $171.0M | — | — | 2.2 | −2.7% |
| LanzaTech Global | $6.17 | 0.00% | $13.6M | 0.1 | — | 0.2 | −0.8% |
| Ginkgo Bioworks | $7.03 | +0.86% | $454.7M | — | — | 4.1 | −59.4% |
| Twist Bioscience | $141.01 | −0.20% | $8.80B | — | — | 20.4 | +23.3% |
| Median | 0.1 | — | 3.1 | −1.7% |